Impact of strict IGF1 control on quality-of-life scores in patients with acromegaly.

ABSTRACT:

Objective

Examine, in a real-world setting, whether strict normalization of modestly elevated insulin-like growth factor 1 (IGF1) results in clinical and health-related quality of life benefits in patients with acromegaly using an open-label, non-randomized, 6-month prospective interventional study.

Methods

In patients with acromegaly and modest IGF1 elevation, strict IGF1 control was achieved by addition or dose escalation of pegvisomant. Clinical and biochemical parameters were assessed at baseline, 1 and 3 months for pegvisomant dose titration, and at 6 months. The Patient-Assessed Acromegaly Symptom Questionnaire (PASQ), the Acromegaly Quality of Life questionnaire (AcroQoL) and the Acromegaly Disease Activity Tool (ACRODAT^®) were completed at baseline and at

SUBMITTER: Gandhi C 

PROVIDER: S-EPMC11825318 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature